| Market Cap | 39.16M | P/E | - | EPS this Y | 98.10% | Ern Qtrly Grth | - |
| Income | -9.96M | Forward P/E | - | EPS next Y | 50.50% | 50D Avg Chg | -19.00% |
| Sales | 408.2k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -19.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -37.00% |
| Recommedations | 2.00 | Quick Ratio | 0.53 | Shares Outstanding | 7.63M | 52W Low Chg | - |
| Insider Own | 10.07% | ROA | -93.46% | Shares Float | 6.83M | Beta | - |
| Inst Own | 8.28% | ROE | -222.30% | Shares Shorted/Prior | 119.59K/276.94K | Price | 3.24 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 40,074 | Target Price | 52.33 |
| Oper. Margin | -35,470.40% | Earnings Date | - | Volume | 40,622 | Change | -12.67% |
Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.